Sponsor |
Trial Name |
Intervention |
Inclusion Criteria |
Other Disease Targeted Treatment Allowed |
Duration |
Target for Recruit- ment |
Georgetown University |
|
Bosentan |
SSc with exercise induced PH |
No |
16 weeks |
40 |
Actelion |
COMPASS 2 |
Bosentan added to Sildenafil |
IPAH, FPAH, APAH, on sildenafil for minimum of 12 weeks |
No |
16 weeks |
250 |
Bayer |
PATENT 2 |
Riociguat |
IPAH |
Yes |
12 weeks + extension |
462 |
United Therapeutics |
ATPAHSS |
Tadalafil and/or ambrisentan |
Systemic Sclerosis with pulmonary hypertension, WHO II or III |
No |
36 weeks |
63 |
Novartis Pharma-ceuticals |
IMPRES |
Imatinib |
IPAH, WHO II to IV |
Yes |
24 weeks |
200 |
Virginia Common-wealth University |
|
Carvedilol |
IPAH or assoc PAH, WHO II to IV |
Yes |
6 months |
24 |
Pfizer |
|
Bosentan +/- sildenafil |
PAH |
Yes |
12 weeks |
106 |
University of Heidelberg Still recruiting |
|
The influence of respiratory and exercise therapy on oxygen uptake, quality of life and right ventricular function |
PAH |
Yes |
15 weeks |
90 |
University of Heidelberg Still recruiting |
|
The influence of respiratory and exercise therapy on 6 minute walk distance and quality of life |
PAH |
Yes |
16 weeks |
34 |
Hospital de Clinicas de Porto Alegre Still recruiting |
|
Inspiratory muscle training |
PAH |
Yes |
8 weeks |
34 |
University of Heidelberg Still recruiting |
|
Exercise training |
PAH |
Yes |
16 weeks |
34 |
Hannover Medical School Still recruiting |
|
3 week In-patient rehabilitation programme |
PAH |
Yes |
3 weeks |
100 |
Seoul National University Still recruiting |
ULTIMATE |
Udenafil |
Mild Pulmonary Hypertension |
Yes |
12 weeks |
40 |
Golden Jubilee National Hospital Still recruiting |
|
Apelin Infusion |
IPAH |
Yes |
1 day (exploratory study) |
63 |
The Cleveland Clinic Ongoing but not recruiting |
|
Oral iron supplementation |
IPAH plus iron defficiency |
Yes |
12 weeks |
25 |
Actelion Still recruiting |
GRIPHON |
Selexipag |
PAH |
Yes |
6 months plus extended study period; long term extension follows on |
670 |
Hillel Yaffe Medical Centre Unknown |
|
Normatec? pump |
Right heart failure and leg oedema |
Yes |
5 days |
20 |
University of Alberta Still recruiting First to Humans, Phase I study. Imperial College also particpating |
|
Dichloroacetate (DCA) |
IPAH, FPAH, APAH |
Yes |
16 weeks |
40 |
Rabin Medical Centre Not yet recruiting |
|
Vardenafil |
PAH |
Iloprost |
14 weeks |
20 |
Stanford University Unknown |
|
Tadalafil, Tyvaso; in combination or stand alone therapy |
IPAH |
No |
48 weeks |
30 |
Stanford University Still recruiting |
|
Tacrolimus (effect on BMPRII signalling) |
IPAH, FPAH, CTDPAH, CHDPAH, APAH, porto pulmonary PH |
Yes, but bosentan excluded |
16 weeks |
40 |
National Institutes of Health Clinical Centre Still recruiting |
|
Spironolactone (effect on inflammation and blood vessel function) |
PAH |
Yes |
24 weeks |
70 |
GSK Still recruiting |
AMBITION |
Tadalafil, ambrisentan; in combination or stand alone therapy |
PAH |
No |
24 weeks plus extended timeline |
545 |
University of Pennsylvania Still recruiting |
|
Anastrolzole (phase II, effect on TAPSE) |
PAH |
Yes |
12 weeks |
18 |
Imperial College London Still recruiting |
|
Ferinject?(Iron injections) (phase II) |
IPAH |
Yes |
12 weeks |
60 |
University of Heidelberg Still recruiting |
|
Exercise and Respiratory Therapy |
Connective Tissue related Pulmonary Hypertension |
Yes |
15 weeks |
45 |
National Institute of Allergy and Infectious Diseases Still recruiting |
|
Rituximab (Phase II) |
Systemic sclerosis pulmonary hypertension |
No |
48 weeks |
80 |
Medical University of Gratz Still recruiting |
|
Ambrisentan |
Porto-pulmonary Hypertnesion |
No |
24 weeks |
24 |
Tufts Medical Centre Still recruiting |
|
Ambrisentan |
Porto-pulmonary Hypertnesion |
No |
24 weeks |
30 |
University of Calafornia Still recruiting |
|
Iloprost |
Congenital Heart Disease PAH |
Yes |
12 weeks |
16 |